Goldline Pharmaceutical IPO
Goldline Pharmaceutical IPO
Overview
Goldline Pharmaceutical IPO is a book build issue of ₹11.61 crores. The issue is entirely a fresh issue of 0.27 crore shares of ₹11.61 crore. Goldline Pharmaceutical IPO opens for subscription on May 12, 2026 and closes on May 14, 2026. The allotment for the Goldline Pharmaceutical IPO is expected to be finalized on May 15, 2026. Goldline Pharmaceutical IPO will list on the BSE SME with a tentative listing date fixed as May 19, 2026. Goldline Pharmaceutical IPO is set issue price band at ₹41 to ₹43 per share. The lot size for an application is 3,000 shares. The minimum amount of investment required by an individual investor (retail) is ₹2,58,000 (6,000 shares) (based on upper price). The minimum lot size for investment in HNI is 3 lots (9,000 shares), amounting to ₹3,87,000. Cumulative Capital Pvt.Ltd. is the book running lead manager and Bigshare Services Pvt.Ltd. is the registrar of the issue.
Issue Size
₹27,00,000
Issue Price
₹12 Cr
Price Band
₹41 – ₹43
Lot Size
3000 shares
Min. Investment
₹1,23,000
Max. Investment
₹1,29,000
Open Date
12 May, 2026
Close Date
14 May, 2026
Allotment
15 May, 2026
Listing
19 May, 2026
Max. Investment
₹1,29,000
Announced
12 May, 2026
Opening Date
12 May, 2026
Closing Date
14 May, 2026
Basis of Allotment
15 May, 2026
Initiation of Refunds
18 May, 2026
Credit of Shares
18 May, 2026
Listing Date
19 May, 2026
Live GMP
Est. Listing: ₹58
Apply via UPI in 5 minutes
Choose your broker • Zero commission on IPO
About Goldline Pharmaceutical IPO
Goldline Pharmaceuticals is engaged in the business of marketing pharmaceutical products under the brand name “Goldline.” Its product range is divided into five segments:
- Goldline Pharma: This category includes 42 products to cater to specialties like Physicians, Orthopedics, ENT, Chest Physicians, General and Specialty Surgery, Gastroenterology, Neurology, and Urology.
- Goldline Cardinal: This category offers 54 products tailored for the Specialty d
Goldline Pharmaceutical IPO Share Price
Issue Breakdown
Shareholding
Dilution: 39.1% increase in shares
Goldline Pharmaceutical IPO Financial Health
Goldline Pharmaceutical Ltd.'s revenue increased by 19% and profit after tax (PAT) rose by 57% between the financial year ending with March 31, 2025 and March 31, 2024.
Goldline Pharmaceutical IPO Lot Size
Investors can bid for a minimum of 6,000 shares and in multiples of 3,000 shares thereof.
| Application | Lots | Shares | Amount |
|---|---|---|---|
| Individual investors (Retail) (Min) | 2 | 6000 | ₹2,58,000 |
| Individual investors (Retail) (Max) | 2 | 6000 | ₹2,58,000 |
| S-HNI (Min) | 3 | 9000 | ₹3,87,000 |
| S-HNI (Max) | 7 | 21000 | ₹9,03,000 |
| B-HNI (Min) | 8 | 24000 | ₹10,32,000 |
(All values in CR)
Goldline Pharmaceutical IPO Valuations
| Metric | Value |
|---|---|
| ROE | 35.84 |
| ROCE | 38.46 |
| Debt/Equity | 1.50 |
| RoNW | 27.38 |
| PAT Margin | 10.10 |
| EBITDA Margin | 20.79 |
| Price to Book Value | 3.47 |
(All values in CR)
Goldline Pharmaceutical IPO Strength & Risk
Goldline Pharmaceutical IPO Strengths
- Operates in the pharmaceutical sector with steady demand potential
- Markets products under its own “Goldline” brand
- Asset-light business model through third-party manufacturing arrangements
- Wide product portfolio across multiple healthcare segments
- Revenue and profit showed consistent growth in FY25
- EBITDA margins improved in FY25 compared to FY24
- Healthy Return on Net Worth (RoNW) indicates improving profitability
- Established distribution and marketing network across multiple states
- Experienced promoters with pharma industry background
- IPO proceeds planned partly for debt reduction, which may improve balance sheet strength
Goldline Pharmaceutical IPO Risks
- SME IPOs generally carry high volatility and low liquidity risk
- Business depends heavily on third-party manufacturers and suppliers
- Faces intense competition in the generic pharmaceutical industry
- Modest scale of operations compared to larger pharma companies
- Financial risk profile has historically been weak with moderate leverage
- Regulatory compliance risks remain high in the pharmaceutical sector
- Brand awareness appears limited compared to established pharma players
- Dependence on distributor and supplier relationships can affect operations if disrupted
- Final IPO valuation, GMP, and subscription response are still uncertain
- Any slowdown in product demand or regulatory issues may impact growth and margins
Goldline Pharmaceutical IPO Subscriptions Status
Goldline Pharmaceutical IPO subscribed 840.74 times. The public issue subscribed 881.15 times in the individual investors category, 180.22 times in QIB (Ex Anchor), and 1,662.04 times in the NII category by May 14, 2026 5:14:34 PM (Day 3).
| Investor Category | Subscription (times) | Shares Offered | Shares bid for | Total Amount (Rs Cr.) |
|---|---|---|---|---|
| Market Maker | 1.00 | 1,38,000 | 1,38,000 | 0.59 |
| Anchor | 1.00 | 7,32,000 | 7,32,000 | 3.15 |
| QIB (Ex Anchor) | 180.22 | 5,40,000 | 9,73,17,000 | 418.46 |
| NII | 1.00 | 3,90,000 | 64,81,95,000 | 2 |
| bNII (> ₹10L) | 2.00 | 2,58,000 | 51,87,36,000 | 2 |
| sNII (< ₹10L) | 980.75 | 1,32,000 | 12,94,59,000 | 556.67 |
| Individual Investors | 881.15 | 9,00,000 | 79,30,38,000 | 3 |
| Total | 840.74 | 18,30,000 | 1,53,85,50,000 | 6 |
Goldline Pharmaceutical IPO GMP
Goldline Pharmaceutical SME IPO last GMP is ₹15, last updated May 14th 2026 05:00 PM. With the price band of 43.00, Goldline Pharmaceutical SME IPO's estimated listing price is ₹58 (cap price + today's GMP).The expected percentage gain/loss per share is 34.88%. >> Goldline Pharmaceutical SME IPO Retail Subject to Sauda: ₹34200 The lowest GMP is ₹0.00, while the highest GMP is ₹25.00.
Last updated 14 May, 2026 · Source: aggregated grey-market dealers
| Date | IPO Price | GMP | Sub2 Sauda | Est. Listing | Est. Profit | Updated |
|---|---|---|---|---|---|---|
| 14 May, 2026 | 43 | ₹15▼ | - | ₹58 (34.88%) | 45000 | 14 May, 2026 |
| 13 May, 2026 | 43 | ₹25▲ | - | ₹68 (58.14%) | 75000 | 13 May, 2026 |
| 12 May, 2026 | 43 | ₹18▲ | - | ₹61 (41.86%) | 54000 | 12 May, 2026 |
| 11 May, 2026 | 43 | ₹17▲ | - | ₹60 (39.53%) | 51000 | 11 May, 2026 |
| 10 May, 2026 | 43 | ₹16▲ | - | ₹59 (37.21%) | 48000 | 10 May, 2026 |
| 09 May, 2026 | 43 | ₹15▲ | - | ₹58 (34.88%) | 45000 | 09 May, 2026 |
| 08 May, 2026 | 43 | ₹8▲ | - | ₹51 (18.60%) | 24000 | 08 May, 2026 |
| 07 May, 2026 | 43 | ₹0 | - | ₹ (%) | - | 07 May, 2026 |
Disclaimer: GMP is an unofficial signal from grey-market dealers and is not regulated by SEBI. Use it alongside subscription data and other research for informed decision-making.
How to Apply for Goldline Pharmaceutical IPO
Login to Your Trading App
Open Zerodha, Upstox, Groww, Angel One, or any brokerage app.
Go to IPO Section
Find Goldline Pharmaceutical IPO under the IPO section. Select it and enter your bid details — choose lot size and price (cut-off price recommended).
Enter UPI ID and Submit
Provide your UPI ID linked to your bank account and submit the application.
Approve Mandate on UPI App
Open your UPI app (Google Pay, PhonePe, Paytm, BHIM) and approve the IPO payment request.
Application Confirmed
Your funds will be blocked in your account until the IPO allotment process is completed.